Compare NTIC & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTIC | ICCC |
|---|---|---|
| Founded | 1970 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.9M | 93.1M |
| IPO Year | 1996 | 1995 |
| Metric | NTIC | ICCC |
|---|---|---|
| Price | $8.02 | $11.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.1K | ★ 26.6K |
| Earning Date | 04-09-2026 | 05-15-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.21 |
| Revenue | ★ $84,234,474.00 | $26,493,169.00 |
| Revenue This Year | $12.49 | N/A |
| Revenue Next Year | $7.64 | N/A |
| P/E Ratio | ★ N/A | $52.67 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $7.16 | $4.52 |
| 52 Week High | $10.03 | $12.10 |
| Indicator | NTIC | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 47.45 | 56.42 |
| Support Level | $7.85 | $5.90 |
| Resistance Level | $8.27 | $12.10 |
| Average True Range (ATR) | 0.13 | 0.48 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 39.59 | 32.17 |
Northern Technologies International Corp is a United States-based firm that develops and markets proprietary, environmentally beneficial products and services world wide either directly or through a network of joint ventures, distributors, and agents. It operates through two segments, which include ZERUST products and services and Nature-Tec products. Its main business is providing corrosion prevention solutions that are marketed under the ZERUST brand. The company also sells a portfolio of bio-based and biodegradable (compostable) polymer resin compounds and finished products marketed under the Nature-Tec brand. The ZERUST brand generates a vast majority of the revenue for the company. The company generates the majority of its revenue in the United States.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.